Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYCLOSET vs CABERGOLINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.
Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by the anterior pituitary gland.
FDA-approved: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,Off-label: Parkinson's disease, hyperprolactinemia, acromegaly, neuroleptic malignant syndrome.
Treatment of hyperprolactinemic disorders (e.g., amenorrhea, galactorrhea, infertility),Prolactin-secreting pituitary adenomas (microadenomas and macroadenomas)
1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.
0.25 mg orally twice weekly, up to 1 mg twice weekly; for hyperprolactinemia, initial 0.25 mg twice weekly, titrate by 0.25 mg every 4 weeks based on prolactin levels.
Terminal elimination half-life is 4–6 hours in patients with normal renal function; clinically, steady-state is reached within 24 hours.
Terminal elimination half-life is 63-68 hours in healthy subjects, allowing for once- or twice-weekly dosing. In hepatic impairment, half-life may be prolonged.
Primarily hepatic via cytochrome P450 3A4 (CYP3A4). Inactive metabolites are excreted mainly in feces (80%) and urine (2-10% unchanged).
Extensively metabolized in the liver, primarily by hydrolysis and minor CYP3A4 involvement.
Renal: ~90% (30% unchanged, rest as inactive metabolites); fecal: ~10%.
Approximately 60-70% of the dose is excreted in feces (primarily as unchanged drug and metabolites), with about 20-30% excreted renally (mostly as metabolites).
~20–30% bound, primarily to albumin.
40-42% bound to plasma proteins, primarily albumin.
0.5–1.0 L/kg, indicating moderate distribution into tissues.
Approximately 100-150 L/kg, indicating extensive tissue distribution; Vd is large (≥100 L/kg) due to high lipophilicity and tissue binding.
Oral: ~65–75% due to first-pass metabolism.
Oral bioavailability is about 40-45% (range 30-60%) due to first-pass metabolism. No parenteral formulations are commonly used.
Contraindicated in patients with e GFR <30 m L/min/1.73 m2. For e GFR 30-50 m L/min/1.73 m2: maximum dose 0.8 mg daily.
No dosage adjustment recommended for mild to moderate renal impairment (Cr Cl >10 m L/min); avoid use in severe renal impairment (Cr Cl <10 m L/min) due to lack of data.
No dose adjustment required for mild hepatic impairment (Child-Pugh class A). Not recommended in moderate to severe hepatic impairment (Child-Pugh class B or C) due to lack of data.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh class C) as elimination may be reduced.
Not approved for pediatric patients. Safety and efficacy in patients <18 years have not been established.
Not FDA approved for pediatric use; limited data: 0.025-0.05 mg/kg once weekly, titrated cautiously based on prolactin levels; maximum 0.1 mg/kg weekly.
Start at 0.8 mg once daily; titrate slowly due to increased risk of orthostatic hypotension and hypoglycemia. Consider renal function and comorbidities.
No specific adjustment recommended; start at lower end of dosing range (0.25 mg twice weekly) due to potential for increased sensitivity and age-related decline in renal function.
None.
Cabergoline is associated with an increased risk of cardiac valve regurgitation, especially at high doses used for Parkinson's disease. The risk appears lower at doses used for hyperprolactinemia, but caution is advised.
Risk of hypotension, especially at initiation of therapy; monitor blood pressure.,May cause somnolence and dizziness; advise patients not to drive or operate machinery until effects are known.,Use with caution in patients with cardiovascular disease, especially those with angina or recent myocardial infarction.,May exacerbate psychotic disorders; use caution in patients with a history of psychosis.,Fibrotic complications (pulmonary, pericardial, retroperitoneal fibrosis) have been reported with ergot-derived dopamine agonists; monitor for symptoms.,Discontinue if signs of cardiac valvulopathy occur.
Cardiac valvulopathy: monitor with echocardiography before and during therapy,Pleural, pericardial, and retroperitoneal fibrosis,Postural hypotension,Impulse control disorders (e.g., pathological gambling, hypersexuality),Remission of prolactinomas may reduce pituitary function
Hypersensitivity to bromocriptine or any component of the formulation.,Concomitant use with CYP3A4 inducers (e.g., rifampin, anticonvulsants) or inhibitors (e.g., azole antifungals, macrolide antibiotics).,Severe ischemic heart disease or peripheral vascular disorders.,Syncopal migraine or history of myocardial infarction with residual arrhythmias.,Uncontrolled hypertension.,Lactation: inhibits lactation, do not use in women with pregnancy or nursing unless essential.
Hypersensitivity to cabergoline or ergot derivatives,Uncontrolled hypertension,History of cardiac valvular disease,Pregnancy: use only if clearly needed (category B)
Avoid alcohol and alcohol-containing products. No specific food interactions; take with or without food. Maintain adequate hydration.
Avoid high-fat meals that may increase absorption variability. No specific food restrictions, but take consistently with meals to maintain stable levels. Grapefruit juice may theoretically increase cabergoline exposure (CYP3A4 inhibition); avoid excessive consumption.
First trimester: insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: no known fetal risks; drug may cause maternal hypoglycemia which can affect fetus.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. In first trimester, theoretical risk of ergot alkaloid-induced uteroplacental vasoconstriction may cause fetal hypoxia; use only if benefit outweighs risk. Second and third trimesters: risk of postpartum hemorrhage and uterine atony if used for lactation suppression; avoid in pregnancy due to potential for fetal harm from dopamine agonist effects.
Not recommended; no data on excretion in human milk. M/P ratio unknown.
Cabergoline suppresses lactation; contraindicated in breastfeeding women because it reduces milk production. If used, discontinue breastfeeding or avoid drug. M/P ratio not established; drug is excreted in rat milk, unknown in humans.
Monitor glucose closely; dose adjustments may be needed due to altered pharmacokinetics in pregnancy (increased clearance). Start at lowest effective dose; titrate based on glycemic response.
No standard dose adjustment recommended; avoid use during pregnancy unless absolutely necessary (e.g., prolactinoma). Pregnancy may alter cabergoline pharmacokinetics (increased volume of distribution, decreased clearance) but specific dose modifications are not established. If used, monitor prolactin levels and clinical response.
Monitor for hypoglycemia, especially in elderly patients or those with renal impairment. Cycloserine may accumulate in renal insufficiency; dose reduction is necessary if Cr Cl < 50 m L/min. Watch for neuropsychiatric effects (seizures, psychosis, depression) and discontinue if severe. Pyridoxine 50-100 mg daily is recommended to reduce neurotoxicity. Avoid alcohol due to increased seizure risk.
Start with 0.25 mg twice weekly, titrate by 0.25 mg every 2-4 weeks based on prolactin levels and tolerability. Maximum dose typically 1 mg twice weekly. May cause orthostatic hypotension; caution when rising from supine position. Use lowest effective dose to minimize risk of valvulopathy, especially with cumulative doses >2 mg/day. Discontinue if signs of cardiac fibrosis. Monitor for impulse control disorders (e.g., hypersexuality, gambling). Avoid in patients with uncontrolled hypertension or pre-existing cardiac valvular disease.
Take exactly as prescribed; do not miss doses or double up.,Report any signs of rash, confusion, dizziness, or unusual behavior immediately.,Avoid alcohol completely while on this medication.,If you have kidney problems, your dose may need adjustment.,Take pyridoxine (vitamin B6) as directed to lower risk of side effects.,Do not drive or operate heavy machinery if you feel drowsy or dizzy.,Complete the full course of therapy even if you feel better.
Take with food to reduce gastrointestinal upset.,Avoid alcohol as it may increase side effects like dizziness or nausea.,Rise slowly from sitting or lying positions to prevent fainting.,Report any new shortness of breath, swelling, or chest pain immediately.,Notify your doctor if you experience unusual urges (gambling, sex, spending).,Do not drive or operate machinery if you feel dizzy or drowsy.,Take exactly as prescribed; do not double the dose if missed.,Store at room temperature away from moisture and heat.
No interactions on record
"Trazodone, a serotonin antagonist and reuptake inhibitor, and cabergoline, a dopamine D2 receptor agonist, exhibit opposing effects on the dopaminergic and serotonergic systems, potentially leading to reduced therapeutic efficacy and increased risk of adverse effects such as serotonin syndrome or dopaminergic toxicity. The combination may precipitate hypertensive crises or cardiac valvulopathy due to additive effects on 5-HT2B receptor activation by cabergoline, while trazodone's blockade of serotonin reuptake can exacerbate serotonin excess. Clinical outcomes include unpredictable blood pressure fluctuations, neuropsychiatric disturbances, and rare but serious cardiovascular events."
"Cabergoline, a dopamine D2 receptor agonist used for hyperprolactinemia, may inhibit the metabolism of methylene blue, a monoamine oxidase inhibitor (MAOI) used for methemoglobinemia. This interaction can lead to elevated methylene blue levels, increasing the risk of serotonin syndrome, characterized by hyperthermia, agitation, and neuromuscular abnormalities. Clinically, patients may present with confusion, tachycardia, and hypertension, necessitating cautious use."
"Cabergoline, a dopaminergic ergot derivative, acts as a vasoconstrictor via agonism of serotonin 5-HT2B and dopamine D1 receptors in vascular smooth muscle. Nadolol, a non-selective beta-blocker, inhibits beta-2 adrenergic receptor-mediated vasodilation, leaving alpha-adrenergic vasoconstriction unopposed. The combined vasoconstrictive effects can lead to additive peripheral and coronary vasoconstriction, potentially causing severe hypertension, myocardial ischemia, or Raynaud's phenomenon."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYCLOSET vs CABERGOLINE, answered by our medical review team.
CYCLOSET is a Dopamine Agonist / Antidiabetic that works by Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.. CABERGOLINE is a Dopamine Agonist that works by Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by the anterior pituitary gland.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYCLOSET and CABERGOLINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYCLOSET is: 1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.. The standard adult dose of CABERGOLINE is: 0.25 mg orally twice weekly, up to 1 mg twice weekly; for hyperprolactinemia, initial 0.25 mg twice weekly, titrate by 0.25 mg every 4 weeks based on prolactin levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYCLOSET and CABERGOLINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYCLOSET is classified as Category C. First trimester: insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: no known fetal risks; drug may cause mate. CABERGOLINE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. In first trimester, theoretical risk of ergot alkaloid-induced uteroplacental vasocon. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.